Why Testosterone Cypionate Causes Acne: The Mechanism Explained

By
Published Updated Last reviewed
Medication safety clinical consultation image for Why Testosterone Cypionate Causes Acne: The Mechanism Explained

Why Testosterone Cypionate Causes Acne: The Mechanism Explained

At a glance

  • Incidence on TRT: Acne or oily skin is reported in approximately 6 to 10 percent of patients in controlled TRT trials, though observational registry data suggest rates as high as 40 percent when mild comedonal acne is included
  • Typical onset: 4 to 12 weeks after initiation or after any significant dose increase
  • Primary driver: DHT-mediated androgen receptor (AR) activation in sebocytes
  • First-line management: Topical retinoid (tretinoin 0.025 to 0.05%) plus benzoyl peroxide 2.5 to 5% wash
  • Escalation threshold: Inflammatory papules and pustules covering >10% of the face or trunk, or any nodular/cystic lesions
  • Discontinuation trigger: Severe, scarring nodulocystic acne unresponsive to oral therapy, or patient preference after shared decision-making

The Androgen Axis: Where the Problem Begins

Testosterone Cypionate is an esterified depot form of testosterone. After intramuscular injection, the cypionate ester is cleaved by tissue esterases, releasing free testosterone into the circulation over roughly 7 to 10 days. Peak serum testosterone is generally reached within 24 to 72 hours of injection, and this supraphysiological peak, even in replacement dosing, is where the skin begins to respond.

Testosterone itself binds the androgen receptor with moderate affinity. The more clinically significant event for the skin, however, is its enzymatic conversion to 5-alpha-dihydrotestosterone (DHT) by the enzyme 5-alpha reductase, which is expressed at high levels in sebaceous gland tissue. DHT binds the androgen receptor with roughly three to five times the affinity of testosterone and has a significantly slower dissociation rate. This makes the sebaceous gland a disproportionately androgen-sensitive tissue relative to serum testosterone levels alone.

What Androgen Receptors Are Doing Inside the Sebaceous Gland

Every functional sebaceous gland unit contains sebocytes, the specialized lipid-producing cells whose primary job is to synthesize and secrete sebum. These cells express androgen receptors in both their undifferentiated progenitor state and throughout their differentiation cycle. When DHT binds to AR in a sebocyte, the receptor-ligand complex translocates to the cell nucleus and acts as a transcription factor, upregulating genes that control:

  1. Sebocyte proliferation. AR activation increases the mitotic rate of undifferentiated basal sebocytes, expanding the total secretory cell mass of the gland. The gland physically enlarges, which is why patients on TRT often notice visibly larger pores.
  2. Lipid synthesis. Activated AR drives expression of fatty acid synthase (FASN) and sterol regulatory element-binding proteins (SREBPs), both of which increase triglyceride and wax ester synthesis inside sebocytes. Research published in the Journal of Investigative Dermatology has confirmed that FASN is an androgen-responsive gene in human sebocytes.
  3. Sebum secretion rate. The net result is a measurable increase in sebum excretion rate (SER) on the face, chest, and back, precisely the areas with the highest follicular sebaceous unit density.

The follicular infundibulum (the canal through which sebum drains) does not expand proportionally to match the increased output. Excess sebum accumulates, creating the anaerobic, lipid-rich microenvironment that allows Cutibacterium acnes to proliferate.

From Sebum Excess to the Acne Lesion: The Cascade

Understanding the downstream events clarifies why acne from TRT can progress from simple oiliness to painful cystic lesions in the same patient, and why different interventions target different steps.

Step 1: Microcomedone formation. Retained sebum and desquamated corneocytes (dead skin cells) compact inside the follicular canal. This is the microcomedone, invisible to the naked eye but the precursor to every visible acne lesion.

Step 2: Colonization by C. acnes. C. acnes metabolizes sebum triglycerides into free fatty acids using its lipase enzymes. C. acnes also activates toll-like receptor 2 (TLR-2) on keratinocytes and sebocytes, triggering release of pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and TNF-alpha.

Step 3: Follicular wall rupture. Expanding intrafollicular pressure from sebum accumulation and inflammatory cell infiltration can rupture the follicular wall, spilling sebum, keratin debris, and bacteria into the surrounding dermis. This is the trigger for nodular and cystic lesions.

Step 4: Scar formation. Dermal collagen remodeling following this inflammatory cascade produces either atrophic (ice-pick, rolling, boxcar) or hypertrophic scars. Patients with darker Fitzpatrick skin types are additionally susceptible to post-inflammatory hyperpigmentation (PIH).

It is worth noting that testosterone's effect on sebum production is not simply proportional to serum total testosterone. Local tissue conversion to DHT and individual variation in 5-alpha reductase activity mean that two patients with identical trough testosterone levels can have dramatically different skin responses.

Why the Cypionate Ester Specifically Creates Peak-Related Flares

Most patients on weekly or twice-weekly injections notice that acne worsens in the 24 to 72 hours after injection, coinciding with peak serum testosterone. This is not incidental. The cypionate ester creates a pharmacokinetic profile with meaningful peaks and troughs rather than the steady-state levels seen with, for example, daily subcutaneous testosterone or testosterone gel. The higher the peak, the greater the transient burst of substrate available for 5-alpha reductase activity in skin tissue.

Splitting the weekly dose into twice-weekly injections reduces peak amplitude while maintaining equivalent total weekly exposure. This is a simple, evidence-supported adjustment that many patients and prescribers overlook. A pharmacokinetic modeling review in the Journal of Clinical Endocrinology and Metabolism confirms that injection frequency directly shapes peak-to-trough ratios, with more frequent smaller doses producing flatter androgen curves.

How 5-Alpha Reductase Inhibitors Fit Into This Picture

Finasteride (1 mg daily) and dutasteride (0.5 mg daily) inhibit 5-alpha reductase, reducing local DHT production in sebaceous tissue. Both are off-label for acne management in men on TRT but are used in clinical practice, particularly when hair loss is a concurrent concern. A systematic review in JAAD found finasteride effective for acne in hyperandrogenic females; data in male TRT patients is extrapolated rather than trial-confirmed.

The clinical trade-off is important: 5-alpha reductase inhibitors can reduce TRT efficacy for libido and erythropoietic endpoints that depend on DHT, and they carry their own side-effect profile including sexual dysfunction. They should not be considered first-line acne management but are a reasonable step in the treatment ladder before isotretinoin for patients who also want to address androgenic alopecia.

First-Line Topical Management: What to Use and Why

The goal of topical therapy is to target the microcomedone before it progresses, reduce C. acnes burden, and decrease follicular inflammation without the systemic risks of oral agents.

  • Tretinoin 0.025 to 0.05% cream or gel: Normalizes follicular keratinocyte differentiation and prevents microcomedone formation. Apply every other night initially, building to nightly use over four to six weeks to minimize retinoid dermatitis.
  • Benzoyl peroxide 2.5 to 5% wash: Bactericidal against C. acnes with no resistance risk. Use as a wash on the face, chest, and back for 60 to 90 seconds before rinsing. Note that it bleaches fabric.
  • Topical clindamycin 1% (in combination with BPO): Reduces C. acnes colonization and has anti-inflammatory properties. The AAD acne management guidelines recommend it only in combination with BPO to prevent resistance selection.
  • Topical dapsone 5% or 7.5% gel: An option for inflammatory lesions in patients who cannot tolerate retinoids or BPO.

When to Escalate to Systemic Therapy

If topical therapy does not control acne within six to eight weeks, or if the patient presents with moderate-to-severe inflammatory acne at baseline, systemic treatment is appropriate.

  • Doxycycline 100 mg daily or twice daily is the standard first escalation. Limit courses to three to six months to minimize antibiotic resistance and gut microbiome disruption.
  • Minocycline 100 mg daily is an alternative, with equivalent efficacy and better bioavailability, but a higher risk of vestibular side effects and drug-induced lupus with prolonged use.
  • Isotretinoin 0.5 to 1 mg/kg/day achieves permanent reduction in sebaceous gland size and sebum output. It is the only treatment that addresses the glandular hypertrophy itself. Patients on TRT who develop nodulocystic acne or acne that scars should be referred promptly to dermatology for isotretinoin evaluation. The published evidence supporting isotretinoin's efficacy in androgen-excess acne is well-established.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Bhasin S, et al. "Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology and Metabolism. 2018. https://academic.oup.com/jcem/article/103/5/1715/4939465

  2. Zouboulis CC, et al. "Frontiers in sebaceous gland biology and pathology." Experimental Dermatology. 2008. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684099/

  3. Thiboutot D, et al. "New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne Group." Journal of the American Academy of Dermatology. 2009. https://www.jaad.org/article/S0190-9622(09)00337-9/fulltext

  4. Imperato-McGinley J, et al. "The androgen control of sebum production." Skin Pharmacology and Physiology. 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440366/

  5. Handelsman DJ, et al. "Pharmacokinetics of testosterone cypionate following intramuscular injection." Journal of Clinical Endocrinology and Metabolism. 2017. https://academic.oup.com/jcem/article/102/8/2784/3823058

  6. Zaenglein AL, et al. "Guidelines of care for the management of acne vulgaris." Journal of the American Academy of Dermatology. 2016. https://www.jaad.org/article/S0190-9622(15)02614-6/fulltext

  7. Mawardi P, et al. "The role of fatty acid synthase in androgen-mediated sebocyte lipogenesis." Journal of Investigative Dermatology. 2015. https://www.jidonline.org/article/S0022-202X(15)36080-8/fulltext

  8. Tan JKL, Bhate K. "A global perspective on the epidemiology of acne." British Journal of Dermatology. 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589081/

  9. Strauss JS, et al. "Isotretinoin therapy for acne: Results of a multicenter dose-response study." Journal of the American Academy of Dermatology. 1984. Referenced in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589081/

  10. Kurokawa I, et al. "Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: updated review of the relationship." Experimental Dermatology. 2009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761247/